samedan logo

 
 
spacer
home > ict > winter 2009 > the latin beat
PUBLICATIONS
International Clinical Trials

The Latin Beat

 

The experience of running clinical trials in Latin America has improved markedly in recent years in line with the breadth of resources and expertise now available in the region. Graciela Rácaro at PAREXEL International examines the pace of evolution during the last decade

Latin America has evolved as an important area for clinical research, and the industry has shown increasing interest in the emerging region that will serve as a potential new end market for biopharmaceutical products. While clinical trial sponsors used to consider Latin America primarily in large studies or for clinical trials that could not achieve the required patient recruitment on time in ‘traditional’ research countries, more recently they have included the region from the beginning when planning their product development programmes.

Latin America has evolved as an important area for clinical research, and the industry has shown increasing interest in the emerging region that will serve as a potential new end market for biopharmaceutical products. While clinical trial sponsors used to consider Latin America primarily in large studies or for clinical trials that could not achieve the required patient recruitment on time in ‘traditional’ research countries, more recently they have included the region from the beginning when planning their product development programmes.

The growth of clinical trials in Latin America (which is linked to FDA/EMEA acceptance of foreign research data, a huge pool of potential trial patients, and the globalisation of clinical research) should be assessed not only in terms of the number of studies conducted in the region, but also through the experience gained during the last few years.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Graciela Rácaro is Senior Director, Clinical Operations, Latin America at PAREXEL International. She is responsible for all clinical and regulatory activities in Latin America. Graciela specialises in drug development and non-clinical and clinical research. Her background includes serving as clinical lead and project manager for Latin American projects as well as global programmes. Prior to joining PAREXEL, Graciela held a clinical management position at Serono International, and previously worked at the clinical research organisation EDYABE and pharmaceutical company Laboratorio Gador, SA. Graciela holds BCh and Pharm degrees from the College of Pharmacy and Biochemistry at the University of Buenos Aires, and completed her Masters in Clinical Research and Clinical Trials Monitoring at the University Maimónides College of Medicine in Buenos Aires. Email: graciela.racaro@parexel.com

 

spacer
Graciela Rácaro
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Entry now open for the PPMA Group Industry Awards 2019

The 2019 PPMA Group Industry Awards will be held at the National Conference Centre (NEC), Birmingham, on the evening of the first day of the PPMA Total Show 2019 – Tuesday, 1 October 2019. 
More info >>

White Papers

What is process characterization?

EXPUTEC

Process characterization is an essential step in the commercialization of a new (biological) drug. For drug product commercialization, manufacturers must validate the drug’s manufacturing process. This ensures that the manufacturing process delivers consistently a quality product and that the patient is not at risk.
More info >>

 
Industry Events

ESMO Targeted Anticancer Therapies Congress 2020

2-4 March 2020, Paris, France

A unique and international mix of experts, researchers and decision makers both from academia and industry across the globe, will convene in Paris for a three-day Congress aiming at exchanging knowledge, experience and research innovations in cancer. TAT 2020 will focus, among others, on novel strategies in immuno-oncology, personalised medicine and molecular tumour boards, preclinical studies to identify effective combination therapies, use of microbiome, tumour agnostic trials, ADC technology, oncolytics, multispecific biological constructs and targeting cytokines. Participating in TAT 2020 will offer you the possibility to take part in interdisciplinary discussions inspiring new ideas and new collaborations.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement